AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25244562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (standardized lesson).
Number of subjects: 900
Study 24073667 — intervention group
Group type: EXPERIMENTAL
Intervention: MUP group (n = 34)
Number of subjects: 69
Study 24073667 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 69
Study 21320119 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (up to 30 mg/kg/day)
Number of subjects: 59
Study 21320119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19229821 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 1,000 IU/day
Number of subjects: 128
Study 19229821 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin D3 supplementation)
Number of subjects: 128
Study 16881778 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 325
Study 15701212 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution
Number of subjects: 68
Study 15701212 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine 0.05% ophthalmic suspension
Number of subjects: 68
Study 11257665 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 73
Study 11257665 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 73
Study 9212965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow mode of Terumo Capiox centrifugal pump
Number of subjects: 11
Study 9212965 — intervention group
Group type: COMPARATOR
Intervention: Intraaortic balloon pumping (IABP)
Number of subjects: 11
Study 9212965 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile mode of the 3M Delphin pump
Number of subjects: 11
Study 9212965 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile CPB
Number of subjects: 11
Study 8426198 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent treatment protocols (H1, H2, H5)
Number of subjects: 1082
Study 8426198 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 1082
Study 8426198 — intervention group
Group type: COMPARATOR
Intervention: Late relapsing patients
Number of subjects: 1082
Study 3304382 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (i.v. 1.5 i.u. kg‐1 body mass bolus or 10 i.u. followed by infusion to overall 1.5 i.u. kg‐1 body mass dose)
Number of subjects: 8
Study 3304382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31752829 — intervention group
Group type: EXPERIMENTAL
Intervention: BV juice (480 ml/day)
Number of subjects: 85
Study 31752829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (480 ml/day)
Number of subjects: 85
Study 28472058 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 87
Study 28472058 — intervention group
Group type: COMPARATOR
Intervention: Bovine lipid extract surfactant
Number of subjects: 87
Study 25928562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (school-based curriculum, out-of-school outreach, community mobilisation, health-worker training in youth-friendly health services)
Number of subjects: 2664
Study 25928562 — intervention group
Group type: COMPARATOR
Intervention: Comparison (community mobilisation and youth-friendly health services training only)
Number of subjects: 2664
Study 23902931 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention based on the Information‐Motivation‐Behavioural Skills (IMB) Model
Number of subjects: 1196
Study 23902931 — intervention group
Group type: COMPARATOR
Intervention: Health education leaflet on sensible drinking
Number of subjects: 1196
Study 21269547 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g EPH (egg-protein hydrolysate)
Number of subjects: 20
Study 21269547 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g EPH
Number of subjects: 20
Study 21269547 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g EPH
Number of subjects: 20
Study 21269547 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g EPH with 2 g MP (milk protein)
Number of subjects: 20
Study 21269547 — intervention group
Group type: COMPARATOR
Intervention: 4 g MP
Number of subjects: 20
Study 19418394 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital image cytometry (DICM)
Number of subjects: 164
Study 19418394 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy protocol
Number of subjects: 164
Study 16952781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypurinol 600 mg/day for 1 month
Number of subjects: 60
Study 16952781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14766718 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice based continuing medical education with coaching on performance review and implementation of new care processes.
Number of subjects: 44
Study 14766718 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 44
Study 11149473 — intervention group
Group type: EXPERIMENTAL
Intervention: Single iv infusion of 90 mg of pamidronate (group A)
Number of subjects: 32
Study 11149473 — intervention group
Group type: EXPERIMENTAL
Intervention: First infusion of 90 mg of pamidronate followed by 30 mg every 3 months (group B)
Number of subjects: 32
Study 11149473 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (group C)
Number of subjects: 32
Study 11149473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pamidronate regimens
Number of subjects: 32
Study 9298517 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms/kg nicotine
Number of subjects: 0
Study 9298517 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg nicotine
Number of subjects: 0
Study 9298517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 8136741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day of ambisome
Number of subjects: 76
Study 8136741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 3119786 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA‐produced gamma‐interferon (3, 30, 300, 1,000, or 3,000 micrograms/m2) administered intravenously over two hours
Number of subjects: 30
Study 3119786 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA‐produced gamma‐interferon (1,000 micrograms/m2) administered continuously over 24 hours
Number of subjects: 30
Study 3119786 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA‐produced gamma‐interferon (1,000 micrograms/m2) administered daily either by two or 24 hour infusion for 14 days
Number of subjects: 30
Study 3119786 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA‐produced gamma‐interferon
Number of subjects: 30
Study 29451869 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating inflatable head pad
Number of subjects: 120
Study 29451869 — intervention group
Group type: COMPARATOR
Intervention: Gel head pad (Control)
Number of subjects: 120
Study 27531486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecobalamin tablets and glutathione injection during chemotherapy
Number of subjects: 94
Study 27531486 — intervention group
Group type: COMPARATOR
Intervention: Glutathione injection only
Number of subjects: 94
Study 24067881 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab therapy (160 mg followed by 80 mg)
Number of subjects: 963
Study 22430274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/d for 4 weeks followed by 2 weeks off treatment (schedule 4/2)
Number of subjects: 292
Study 22430274 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 37.5 mg/d on the continuous daily dosing (CDD) schedule
Number of subjects: 292
Study 22430274 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule 4/2
Number of subjects: 292
Study 22430274 — intervention group
Group type: COMPARATOR
Intervention: Schedule 4/2 and CDD
Number of subjects: 292
Study 20521015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysglycemic group (n=39)
Number of subjects: 70
Study 20521015 — intervention group
Group type: COMPARATOR
Intervention: Euglycemic group (n=31)
Number of subjects: 70
Study 20521015 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference vessel diameter (RVD)
Number of subjects: 70
Study 20521015 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent area (SA)
Number of subjects: 70
Study 20521015 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent volume (SV)
Number of subjects: 70
Study 20521015 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 70
Study 20521015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 70
Study 18674743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 1820
Study 17707978 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytostanol supplementation (1.6 g of free phytostanol equivalents as phytostanol ester, 2.7 g stanol esters)
Number of subjects: 30
Study 17707978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14521249 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention program delivered via local mass media and reinforced by indigenous volunteers
Number of subjects: 0
Study 14521249 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (control group)
Number of subjects: 0
Study 10960756 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (self-etching primer) alone
Number of subjects: 0
Study 10960756 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V after K-etchant (40% phosphoric acid gel) pre-conditioning
Number of subjects: 0
Study 10960756 — intervention group
Group type: COMPARATOR
Intervention: Control group (artificially prepared wedge-shaped lesions)
Number of subjects: 0
Study 8982778 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide immunotherapy (IPC-1 and IPC-2, 250 micrograms, s.c. injections weekly for 4 weeks)
Number of subjects: 42
Study 8982778 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide immunotherapy
Number of subjects: 42
Study 8982778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1451645 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (30 mg/kg)
Number of subjects: 20
Study 1451645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6431573 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg oral dose of brotizolam
Number of subjects: 12
Study 30887937 — intervention group
Group type: EXPERIMENTAL
Intervention: Green banana biomass (40 g) (RS: approximately 4·5 g)
Number of subjects: 113
Study 30887937 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 113
Study 30086659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive behavioral therapy (CBT) stress management program
Number of subjects: 362
Study 30086659 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 362
Study 26968269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol alone (0.03 ml/kg/dose)
Number of subjects: 200
Study 26968269 — intervention group
Group type: COMPARATOR
Intervention: Nebulised salbutamol with ipratropium bromide (250 ug/dose)
Number of subjects: 200
Study 25224654 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-eluting bioabsorbable implant placed in the office after ESS
Number of subjects: 20
Study 25224654 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-eluting bioabsorbable implant
Number of subjects: 20
Study 22785573 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine combination regimen
Number of subjects: 263
Study 22785573 — intervention group
Group type: COMPARATOR
Intervention: Increased ARB regimen
Number of subjects: 263
Study 19288975 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100-200 mg/d)
Number of subjects: 26
Study 19288975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17694684 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental magnesium infusion (2 g after induction of anesthesia, then 8 g upon arrival in ICU until 24 hr)
Number of subjects: 345
Study 17694684 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium infusion)
Number of subjects: 345
Study 16979991 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 1.35 +/- 0.23 g/d (group 1)
Number of subjects: 55
Study 16979991 — intervention group
Group type: COMPARATOR
Intervention: MMF 2 g/d (group 2)
Number of subjects: 55
Study 12553918 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal bisection task
Number of subjects: 3
Study 12553918 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical bisection task
Number of subjects: 3
Study 10563400 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g meropenem tds
Number of subjects: 83
Study 10563400 — intervention group
Group type: COMPARATOR
Intervention: amikacin 15 mg/kg single dose daily plus ceftazidime 2 g tds
Number of subjects: 83
Study 8894145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (120 mg for Group I, 180 mg for Group II, 240 mg for Group III) with daily infusions of either 30 mg or 60 mg for 2 years.
Number of subjects: 71
Study 8894145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (60 mg infusions) for 2 years.
Number of subjects: 71
Study 8894145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium treatment.
Number of subjects: 71
Study 1829841 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting (Palmaz stent)
Number of subjects: 131
Study 1829841 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty (traditional balloon angioplasty)
Number of subjects: 131
Study 6395060 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone sponge soaked in antibiotic solution for at least 30 minutes prior to insertion
Number of subjects: 921
Study 6395060 — intervention group
Group type: COMPARATOR
Intervention: Silicone sponge not soaked in antibiotic solution
Number of subjects: 921
Study 6395060 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of multiple episcleral sponges
Number of subjects: 921
Study 30468626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue of the first dorsal interosseous muscle (FDI) through two 100‐s index finger abduction maximum voluntary isometric contractions (MVICs)
Number of subjects: 15
Study 30468626 — intervention group
Group type: COMPARATOR
Intervention: Rest for 5 minutes (control group)
Number of subjects: 15
Study 27377790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-phone based home telehealth (MTH) intervention
Number of subjects: 81
Study 27377790 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study 26703193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (IV TXA) 2 g
Number of subjects: 139
Study 26703193 — intervention group
Group type: COMPARATOR
Intervention: Topical Tranexamic Acid (Topical TXA) 2 g
Number of subjects: 139
Study 26703193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (IV TXA)
Number of subjects: 139
Study 26703193 — intervention group
Group type: COMPARATOR
Intervention: Topical Tranexamic Acid (Topical TXA)
Number of subjects: 139
Study 26703193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and Topical Tranexamic Acid
Number of subjects: 139
Study 25234206 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-pressure-lowering treatment (perindopril and indapamide)
Number of subjects: 8494
Study 25234206 — intervention group
Group type: COMPARATOR
Intervention: Intensive glucose control
Number of subjects: 8494
Study 22072050 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radioactive iodine treatment
Number of subjects: 44
Study 22072050 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant radioactive iodine treatment
Number of subjects: 44
Study 19284641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric treatment at 1.3 atm and 24% oxygen (treatment group, n = 33)
Number of subjects: 62
Study 19284641 — intervention group
Group type: COMPARATOR
Intervention: Slightly pressurized room air at 1.03 atm and 21% oxygen (control group, n = 29)
Number of subjects: 62
Study 17542615 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g dose of steamed red cabbage
Number of subjects: 12
Study 17542615 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g dose of steamed red cabbage
Number of subjects: 12
Study 17542615 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin metabolites
Number of subjects: 12
Study 17542615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacylated anthocyanins
Number of subjects: 12
Study 16327112 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS and recidivism risk reduction intervention
Number of subjects: 116
Study 16327112 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study 11356211 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid treatment
Number of subjects: 18
Study 11356211 — intervention group
Group type: EXPERIMENTAL
Intervention: Er‐YAG laser treatment at 2Hz and 250mJ on dentin and 300mJ on enamel
Number of subjects: 18
Study 11356211 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment followed by acid etching
Number of subjects: 18
Study 11356211 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study 9481883 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 14
Study 9481883 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 14
Study 9481883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine challenge test
Number of subjects: 14
Study 9481883 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects during challenge test
Number of subjects: 14
Study 7884663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline tablets (1‐mg single oral dose)
Number of subjects: 12
Study 7884663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline solution (1‐mg single oral dose)
Number of subjects: 12
Study 7884663 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline tablets
Number of subjects: 12
Study 7884663 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline solution
Number of subjects: 12
Study 7884663 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline tablets vs solution
Number of subjects: 12
Study 2874821 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5‐20 mg twice daily
Number of subjects: 101
Study 2874821 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine 25‐100 mg twice daily
Number of subjects: 101
Study 29774642 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropunch blepharopeeling (MBP)
Number of subjects: 22
Study 29774642 — intervention group
Group type: COMPARATOR
Intervention: Blepharoplasty (BP)
Number of subjects: 22
Study 26614823 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral ranolazine 500-1000 mg twice daily for 2 weeks
Number of subjects: 128
Study 26614823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 24783602 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting group (patients instructed to count numbers backwards starting from 100 during propofol injection)
Number of subjects: 91
Study 24783602 — intervention group
Group type: COMPARATOR
Intervention: Non-counting group (patients injected with propofol without any instructions)
Number of subjects: 91
Study 24783602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (counting and non-counting)
Number of subjects: 91
Study 24121454 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshajinkigan (TJ-107) 7.5 g daily
Number of subjects: 89
Study 24121454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 21148246 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed dietary phosphate restriction (≤ 870 mg, 871 to 999 mg, 1000 mg, 1001 to 2000 mg)
Number of subjects: 1751
Study 21148246 — intervention group
Group type: COMPARATOR
Intervention: No phosphate restriction
Number of subjects: 1751
Study 18679150 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula for catheter insertion length (insertional length (cm) = (4 x birth weight [kg]) + 7)
Number of subjects: 74
Study 18679150 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula for catheter insertion length
Number of subjects: 74
Study 18679150 — intervention group
Group type: COMPARATOR
Intervention: Current practice using a nomogram derived from Dunn (control)
Number of subjects: 74
Study 16531446 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. carperitide, 0.2 microg kg(‐1) min(‐1)
Number of subjects: 97
Study 16531446 — intervention group
Group type: COMPARATOR
Intervention: i.v. normal saline (0.9% saline)
Number of subjects: 97
Study 12682480 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 30
Study 12682480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 30
Study 12682480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11109471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesar therapy
Number of subjects: 222
Study 11109471 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment by general practitioner
Number of subjects: 222
Study 9184781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 144
Study 9184781 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 1347812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine device (IUD)
Number of subjects: 22908
Study 7169652 — intervention group
Group type: EXPERIMENTAL
Intervention: Drained group
Number of subjects: 76
Study 7169652 — intervention group
Group type: COMPARATOR
Intervention: Non-drained group
Number of subjects: 76
Study 7169652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 30732961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral level IB targeted (A)
Number of subjects: 86
Study 30732961 — intervention group
Group type: COMPARATOR
Intervention: Bilateral IB spared (C)
Number of subjects: 86
Study 30732961 — intervention group
Group type: EXPERIMENTAL
Intervention: Single level IB targeted (B)
Number of subjects: 86